These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 29847852)

  • 1. Counterpoint: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Abiraterone.
    Jones RJ
    Oncology (Williston Park); 2018 May; 32(5):223, 226-7, 247. PubMed ID: 29847852
    [No Abstract]   [Full Text] [Related]  

  • 2. Point: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Chemotherapy.
    Isaacsson Velho P; Eisenberger MA
    Oncology (Williston Park); 2018 May; 32(5):223-6. PubMed ID: 29847851
    [No Abstract]   [Full Text] [Related]  

  • 3. The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?
    Aoun F; El Rassy E; Sleilaty G; Assi T; Bakouny Z; Kattan J
    Future Oncol; 2017 Dec; 13(30):2785-2790. PubMed ID: 29188727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling Clinical Outcomes in Prostate Cancer: Application and Validation of the Discrete Event Simulation Approach.
    Pan F; Reifsnider O; Zheng Y; Proskorovsky I; Li T; He J; Sorensen SV
    Value Health; 2018 Apr; 21(4):416-422. PubMed ID: 29680098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
    Saad F; Shore N; Van Poppel H; Rathkopf DE; Smith MR; de Bono JS; Logothetis CJ; de Souza P; Fizazi K; Mulders PF; Mainwaring P; Hainsworth JD; Beer TM; North S; Fradet Y; Griffin TA; De Porre P; Londhe A; Kheoh T; Small EJ; Scher HI; Molina A; Ryan CJ
    Eur Urol; 2015 Oct; 68(4):570-7. PubMed ID: 25985882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review.
    Caffo O; Veccia A; Kinspergher S; Maines F
    Future Oncol; 2018 Feb; 14(5):431-442. PubMed ID: 29350549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warning against second-generation antiandrogen for metastatic castration sensitive prostate cancer.
    Inoue T; Sasaki T; Kato M; Masui S; Nishikawa K
    BJU Int; 2021 Nov; 128(5):550. PubMed ID: 34333840
    [No Abstract]   [Full Text] [Related]  

  • 8. First-line abiraterone improves survival in prostate cancer.
    Brower V
    Lancet Oncol; 2017 Jul; 18(7):e374. PubMed ID: 28602778
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical Trials of Metastatic Castration-sensitive Prostate Cancer: Recent Progress and New Horizons.
    Hamid AA; Morris MJ; Davis ID
    Eur Urol Focus; 2019 Mar; 5(2):165-167. PubMed ID: 30559064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations.
    Yu EY; Gillessen S; Mottet N
    Eur Urol Focus; 2019 Mar; 5(2):162-164. PubMed ID: 30287277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7.
    Lu K
    Eur Urol; 2015 Sep; 68(3):e55-6. PubMed ID: 25865060
    [No Abstract]   [Full Text] [Related]  

  • 12. Osteoclast inhibitors in advanced prostate cancer: does the benefit extend beyond skeletal-related events?
    Geynisman DM; Ross EA; Plimack ER
    Eur Urol; 2015 Oct; 68(4):578-80. PubMed ID: 26116295
    [No Abstract]   [Full Text] [Related]  

  • 13. Burden of disease matters when it comes to systemic therapy for prostate cancer.
    Harrison MR; Armstrong AJ
    Eur Urol; 2015 Mar; 67(3):448-50. PubMed ID: 24612662
    [No Abstract]   [Full Text] [Related]  

  • 14. [A Case of Fulminant Hepatitis after Administration of Abiraterone Acetate].
    Yumiba S; Komori K; Iwanishi T; Koida Y; Kobayashi M; Ono Y
    Hinyokika Kiyo; 2017 Nov; 63(11):479-482. PubMed ID: 29232800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies.
    Small EJ
    Cancer Cell; 2017 Jul; 32(1):6-8. PubMed ID: 28697343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reply to Kevin Lu's letter to the editor re: Arun A. Azad, Bernhard J. Eigl, Raya Leibowitz-Amit, et al. outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status. Eur Urol 2015;67:441-7.
    Azad AA; Chi KN
    Eur Urol; 2015 Sep; 68(3):e57-8. PubMed ID: 25864159
    [No Abstract]   [Full Text] [Related]  

  • 17. How Reliable are Trial-based Prognostic Models in Real-world Patients with Metastatic Castration-resistant Prostate Cancer?
    Seyednasrollah F; Mahmoudian M; Rautakorpi L; Hirvonen O; Laitinen T; Jyrkkiö S; Elo LL
    Eur Urol; 2017 May; 71(5):838-840. PubMed ID: 28189430
    [No Abstract]   [Full Text] [Related]  

  • 18. Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation.
    Prati V; Ruatta F; Aversa C; Gernone A; Galizia D; Bonzano A; Torino S; Nuzzolese I; Marandino L; Aglietta M; Ortega C
    Future Oncol; 2018 Feb; 14(5):443-448. PubMed ID: 29318908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.
    Harland S; Staffurth J; Molina A; Hao Y; Gagnon DD; Sternberg CN; Cella D; Fizazi K; Logothetis CJ; Kheoh T; Haqq CM; de Bono JS; Scher HI;
    Eur J Cancer; 2013 Nov; 49(17):3648-57. PubMed ID: 23973186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.
    Arrabal-Martín M; Anglada-Curado F; Cózar-Olmo JM; Soler-Martínez J; Moreno-Jiménez J; Castiñeiras-Fernández J; Ledo-Cepero MJ; Beardo-Villar P; Requena-Tapia MJ; Zuluaga-Gómez A;
    Actas Urol Esp; 2014 Jun; 38(5):327-33. PubMed ID: 24342031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.